<p>Compass Therapeutics, Inc.（納斯達克代碼：CMPX - 獲取免費報告）在週二的午盤交易中股價上漲了 4.5%。該股票最高交易價格為 5.39 美元，最後交易價格為 5.38 美元。午盤交易中大約交易了 1,662,732 股，較平均每日交易量 1,705,218 股下降了 2%。該股票此前收盤價為 5.15 美元。</p>
<p>獲取 <strong>Compass Therapeutics</strong> 的提醒：</p>
<h2>華爾街分析師觀點</h2>
<ul>
<li>頂級 3 家高動量公司分析師仍然看好</li>
</ul>
<p>多位研究分析師對該股票發表了看法。JMP Securities 在 12 月 3 日的研究報告中將 Compass Therapeutics 的目標股價設定為 10.00 美元。Cantor Fitzgerald 在 12 月 3 日的研究報告中開始覆蓋 Compass Therapeutics 的股票，並給予 “增持” 評級。Canaccord Genuity Group 在 12 月 3 日的研究報告中開始覆蓋 Compass Therapeutics 的股票，給予 “買入” 評級和 10.00 美元的目標價格。Citizens Jmp 在 12 月 3 日的研究報告中開始覆蓋 Compass Therapeutics，給予 “市場表現優於大盤” 評級和 10.00 美元的目標股價。最後，Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Compass Therapeutics 的 “賣出（d-）” 評級。一位分析師給予該股票 “強烈買入” 評級，十三位給予 “買入” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，共識目標價格為 12.23 美元。</p>
<p><strong>閲讀我們關於 CMPX 的最新研究報告</strong></p>
<h2>Compass Therapeutics 價格表現</h2>
<p>該公司的市值為 9.5689 億美元，市盈率為-11.96，貝塔值為 1.44。該公司的 50 日移動平均線為 4.81 美元，200 日移動平均線為 3.78 美元。</p>
<p>Compass Therapeutics（納斯達克代碼：CMPX - 獲取免費報告）最近在 11 月 5 日發佈了季度財報。該公司報告每股收益為（0.08 美元），超出分析師共識預期的（0.14 美元）0.06 美元。整體來看，股票分析師預計 Compass Therapeutics, Inc.在當前財政年度將發佈-0.36 美元的每股收益。</p>
<h2>對 Compass Therapeutics 的對沖基金觀點</h2>
<p>機構投資者最近增持或減持了該公司的股份。Russell Investments Group Ltd.在第三季度將其在 Compass Therapeutics 的股份增加了 3,933.7%。Russell Investments Group Ltd.目前擁有該公司 7,785 股股票，價值 27,000 美元，此前在上個季度購買了 7,592 股。Apollon Wealth Management LLC 在第三季度購買了 Compass Therapeutics 的新股份，價值 35,000 美元。CIBC Bancorp USA Inc.在第三季度收購了 Compass Therapeutics 的新股份，價值 37,000 美元。Creative Planning 在第二季度購買了 Compass Therapeutics 的新頭寸，價值 30,000 美元。最後，Victory Capital Management Inc.在第三季度增持了 Compass Therapeutics 的股份 20.6%。Victory Capital Management Inc.目前擁有該公司 12,652 股股票，價值 44,000 美元，此前在上個季度購買了 2,164 股。68.43% 的股票目前由機構投資者和對沖基金持有。</p>
<h2>Compass Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Compass Therapeutics, Inc 是一家臨牀階段的生物技術公司，致力於新型免疫腫瘤療法的發現和開發。公司總部位於馬薩諸塞州劍橋，專注於工程化單克隆抗體候選藥物，旨在增強 T 細胞介導的抗腫瘤反應。Compass 利用專有抗體平台識別和優化調節免疫檢查點通路和腫瘤微環境的生物製劑。</p>
<p>該公司的主要項目包括 CTX-471，一種雙特異性抗體，靶向 PD-1 和 PD-L1 檢查點，以及 DSP107，一種 CD47-SIRPα通路調節劑，旨在破壞癌細胞上的 “別吃我” 信號。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Compass Therapeutics</li>
<li>請勿刪除，立即閲讀</li>
<li>崩盤已經開始（大多數人只是不知道而已）</li>
<li>警報：在 2026 年 1 月之前拋售這 5 只股票！</li>
<li>[無腦黃金投資]：“給我一個更好的投資。”</li>
<li>投資者警報：微型 “3 美元人工智能奇蹟股票” 即將爆發</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Compass Therapeutics 嗎？</h2>
<p>在你考慮 Compass Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Compass Therapeutics 並不在名單上。</p>
<p>雖然 Compass Therapeutics 目前在分析師中有適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CMPX

<p>Compass Therapeutics（納斯達克代碼：CMPX）股價在午盤交易中上漲 4.5%，至 5.38 美元，交易量約為 166 萬股。分析師設定的目標價為 10.00 美元，評級範圍從強烈買入到賣出。該公司報告每股收益為（0.08 美元），超出預期。機構投資者持有 68.43% 的股份。Compass Therapeutics 專注於開發免疫腫瘤療法，主要項目針對 PD-1 和 CD47 通路</p>

<p>Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) shares rose 4.5% during mid-day trading on Tuesday . The stock traded as high as $5.39 and last traded at $5.38. Approximately 1,662,732 shares were traded during mid-day trading, a decline of 2% from the average daily volume of 1,705,218 shares. The stock had previously closed at $5.15.</p>
<div class="lb-trans"><p>Compass Therapeutics, Inc.（納斯達克代碼：CMPX - 獲取免費報告）在週二的午盤交易中股價上漲了 4.5%。該股票最高交易價格為 5.39 美元，最後交易價格為 5.38 美元。午盤交易中大約交易了 1,662,732 股，較平均每日交易量 1,705,218 股下降了 2%。該股票此前收盤價為 5.15 美元。</p>
</div><p>Get <strong>Compass Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Compass Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><ul>
<li>Top 3 High-Momentum Companies Analysts Are Still Bullish On</li>
</ul>
<div class="lb-trans"><ul>
<li>頂級 3 家高動量公司分析師仍然看好</li>
</ul>
</div><p>A number of research analysts have weighed in on the stock. JMP Securities set a $10.00 price target on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. Cantor Fitzgerald began coverage on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. They issued an &#34;overweight&#34; rating on the stock. Canaccord Genuity Group started coverage on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. They issued a &#34;buy&#34; rating and a $10.00 target price for the company. Citizens Jmp began coverage on Compass Therapeutics in a research note on Wednesday, December 3rd. They issued a &#34;market outperform&#34; rating and a $10.00 price target on the stock. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Compass Therapeutics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $12.23.</p>
<div class="lb-trans"><p>多位研究分析師對該股票發表了看法。JMP Securities 在 12 月 3 日的研究報告中將 Compass Therapeutics 的目標股價設定為 10.00 美元。Cantor Fitzgerald 在 12 月 3 日的研究報告中開始覆蓋 Compass Therapeutics 的股票，並給予 “增持” 評級。Canaccord Genuity Group 在 12 月 3 日的研究報告中開始覆蓋 Compass Therapeutics 的股票，給予 “買入” 評級和 10.00 美元的目標價格。Citizens Jmp 在 12 月 3 日的研究報告中開始覆蓋 Compass Therapeutics，給予 “市場表現優於大盤” 評級和 10.00 美元的目標股價。最後，Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Compass Therapeutics 的 “賣出（d-）” 評級。一位分析師給予該股票 “強烈買入” 評級，十三位給予 “買入” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，共識目標價格為 12.23 美元。</p>
</div><p><strong>Read Our Latest Research Report on CMPX</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 CMPX 的最新研究報告</strong></p>
</div><h2>Compass Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Compass Therapeutics 價格表現</h2>
</div><p>The firm has a market cap of $956.89 million, a price-to-earnings ratio of -11.96 and a beta of 1.44. The business has a 50-day moving average of $4.81 and a 200-day moving average of $3.78.</p>
<div class="lb-trans"><p>該公司的市值為 9.5689 億美元，市盈率為-11.96，貝塔值為 1.44。該公司的 50 日移動平均線為 4.81 美元，200 日移動平均線為 3.78 美元。</p>
</div><p>Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.06. As a group, equities analysts anticipate that Compass Therapeutics, Inc. will post -0.36 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Compass Therapeutics（納斯達克代碼：CMPX - 獲取免費報告）最近在 11 月 5 日發佈了季度財報。該公司報告每股收益為（0.08 美元），超出分析師共識預期的（0.14 美元）0.06 美元。整體來看，股票分析師預計 Compass Therapeutics, Inc.在當前財政年度將發佈-0.36 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Compass Therapeutics</h2>
<div class="lb-trans"><h2>對 Compass Therapeutics 的對沖基金觀點</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. increased its stake in shares of Compass Therapeutics by 3,933.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company's stock worth $27,000 after purchasing an additional 7,592 shares during the last quarter. Apollon Wealth Management LLC bought a new stake in Compass Therapeutics in the 3rd quarter valued at $35,000. CIBC Bancorp USA Inc. acquired a new stake in Compass Therapeutics during the 3rd quarter valued at $37,000. Creative Planning bought a new position in Compass Therapeutics during the second quarter worth $30,000. Finally, Victory Capital Management Inc. increased its holdings in shares of Compass Therapeutics by 20.6% in the third quarter. Victory Capital Management Inc. now owns 12,652 shares of the company's stock valued at $44,000 after purchasing an additional 2,164 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>機構投資者最近增持或減持了該公司的股份。Russell Investments Group Ltd.在第三季度將其在 Compass Therapeutics 的股份增加了 3,933.7%。Russell Investments Group Ltd.目前擁有該公司 7,785 股股票，價值 27,000 美元，此前在上個季度購買了 7,592 股。Apollon Wealth Management LLC 在第三季度購買了 Compass Therapeutics 的新股份，價值 35,000 美元。CIBC Bancorp USA Inc.在第三季度收購了 Compass Therapeutics 的新股份，價值 37,000 美元。Creative Planning 在第二季度購買了 Compass Therapeutics 的新頭寸，價值 30,000 美元。最後，Victory Capital Management Inc.在第三季度增持了 Compass Therapeutics 的股份 20.6%。Victory Capital Management Inc.目前擁有該公司 12,652 股股票，價值 44,000 美元，此前在上個季度購買了 2,164 股。68.43% 的股票目前由機構投資者和對沖基金持有。</p>
</div><h2>Compass Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Compass Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.</p>
<div class="lb-trans"><p>Compass Therapeutics, Inc 是一家臨牀階段的生物技術公司，致力於新型免疫腫瘤療法的發現和開發。公司總部位於馬薩諸塞州劍橋，專注於工程化單克隆抗體候選藥物，旨在增強 T 細胞介導的抗腫瘤反應。Compass 利用專有抗體平台識別和優化調節免疫檢查點通路和腫瘤微環境的生物製劑。</p>
</div><p>The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.</p>
<div class="lb-trans"><p>該公司的主要項目包括 CTX-471，一種雙特異性抗體，靶向 PD-1 和 PD-L1 檢查點，以及 DSP107，一種 CD47-SIRPα通路調節劑，旨在破壞癌細胞上的 “別吃我” 信號。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Compass Therapeutics</li>
<li>Do not delete, read immediately</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>[No Brainer Gold Play]: “Show me a better investment.”</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Compass Therapeutics</li>
<li>請勿刪除，立即閲讀</li>
<li>崩盤已經開始（大多數人只是不知道而已）</li>
<li>警報：在 2026 年 1 月之前拋售這 5 只股票！</li>
<li>[無腦黃金投資]：“給我一個更好的投資。”</li>
<li>投資者警報：微型 “3 美元人工智能奇蹟股票” 即將爆發</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Compass Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Compass Therapeutics 嗎？</h2>
</div><p>Before you consider Compass Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Compass Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Compass Therapeutics 並不在名單上。</p>
</div><p>While Compass Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Compass Therapeutics 目前在分析師中有適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Compass Therapeutics (NASDAQ:CMPX) 股價上漲 4.5% - 接下來會如何發展？